Early Antibiotic Administration in Hospitalized Patients with Solid Tumor Malignancies: Pull the Trigger, or Take a Deep Breath?
This activity has been archived and credit is no longer available.
In this presentation, Dr. Benjamin Musher discusses common misconceptions about immunosuppression in patients with cancer. He differentiates between patients with solid tumors versus those with hematologic tumors, and compares typical immunocompetence in these patient populations.
This Baylor St. Luke's Medical Center Internal Medicine Grand Rounds session took place on Friday, December 3, 2021 at 12:15 P.M.
Activity Information
This activity has been archived and credit is no longer available.
Needs Statement
Clinicians and other healthcare professionals in general internal medicine, and internal medicine and surgical subspecialties at Baylor St. Luke's Medical Center need to be regularly updated with best practices, recent advances and guidelines in the fields of hospital medicine, general internal medicine, multidisciplinary care, and coordination of transitions in care. The conference aims to increase knowledge of the learners in these topics, and to implement the advances and guidelines in clinical practice to enhance the quality of patient care and outcomes.
Educational Objectives
At the conclusion of the session, the participants should be able to:
- Distinguish which clinical parameters drive early antibiotic administration at Baylor St. Luke’s Medical Center.
- Recognize that these clinical parameters may not be accurate indicators of serious bacterial infections.
- Perceive that all cancer patients are not immunosuppressed.
- Demonstrate greater understanding of the downsides to empiric early antibiotic administration.
Target Audience
Professional Categories
- Physicians
- Fellows
- Residents
- Nurses
- Other Health Professionals
Specialties
- Family and Community Medicine
- Internal Medicine
Interest Groups
- Hospital Medicine
- Primary Care
Accreditation/Credit Designation
Baylor College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Baylor College of Medicine designates this enduring material activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Activity Director
Term of Approval
December 1, 2021 through December 31, 2023. Original release date: December 1, 2021.
Disclosure Policy
Baylor College of Medicine (BCM) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education (CME) for physicians. BCM is committed to sponsoring CE activities that are scientifically based, accurate, current, and objectively presented.
In accordance with the ACCME Standards for Commercial Support, BCM has implemented a mechanism requiring everyone in a position to control the content of an educational activity (i.e., directors, planning committee members, faculty) to disclose any relevant financial relationships with commercial interests (drug/device companies) and manage/resolve any conflicts of interest prior to the activity. Individuals must disclose to participants the existence or non-existence of financial relationships at the time of the activity or within 24 months prior.
In addition, BCM has requested activity faculty/presenters to disclose to participants any unlabeled use or investigational use of pharmaceutical/device products; to use scientific or generic names (not trade names) in referring to products; and, if necessary to use a trade name, to use the names of similar products or those within a class. Faculty/presenters have also been requested to adhere to the ACCME's validation of clinical content statements.
BCM does not view the existence of financial relationships with commercial interests as implying bias or decreasing the value of a presentation. It is up to participants to determine whether the relationships influence the activity faculty with regard to exposition or conclusions. If at any time during this activity you feel that there has been commercial/promotional bias, notify the Activity Director or Activity Coordinator. Please answer the questions about balance and objectivity in the activity evaluation candidly.
All of the relevant financial relationships listed for these individuals have been mitigated.
Disclosures
The following individual(s) has/have reported financial or other relationship(s) with commercial entities whose products/services may relate to the educational content of this activity:
Presenter
-
Benjamin Leon Musher, M.D.
Associate Professor
Baylor College of Medicine
Disclosure:
- Research Support: LOKON Pharma
- Consultancy: Marker Therapeutics; Xbiotech
- Honorarium Recipient: Ipson; Pfizer
Activity Director
Planning Committee Members
-
Khannan Athreya, M.D.
Assistant Professor
Baylor College of Medicine
Disclosure:
Nothing to disclose.
-
-
-
Chimkama Nguzi Ibe, M.D.
Assistant Professor
Baylor College of Medicine
Disclosure:
Nothing to disclose.
-
Sung In Hillary Kim-Vences, M.D.
Assistant Professor
Baylor College of Medicine
Disclosure:
Nothing to disclose.
-
-
Health Topics
Presenter: